Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Common Equity of $636.0 million for Q1 2026, up 5.22% year-over-year from $604.5 million in Q1 2025, and down 11.93% quarter-over-quarter from $722.2 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Common Equity (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Common Equity history runs 14 years deep, the most recent figure standing at $636.0 million for Q1 2026.
- In Q1 2026, Common Equity rose 5.22% year-over-year to $636.0 million; the TTM figure through Mar 2026 stood at $636.0 million (up 5.22% YoY), while the FY2025 annual figure was $722.2 million, up 7.52% from the prior year.
- Common Equity for Q1 2026 stood at $636.0 million, down from $722.2 million in the prior quarter.
- The five-year high for Common Equity was $722.2 million in Q4 2025, with the low at $141.9 million in Q2 2022.
- The 5-year median for Common Equity is $503.0 million (2025), against an average of $469.2 million.
- The sharpest annual moves came in 2023 and 2024: Common Equity plunged 30.67% in 2023, then jumped 149.49% in 2024.
- Viridian Therapeutics, Inc.\DE's Common Equity stood at $395.1 million in 2022, then increased by 11.89% to $442.0 million in 2023, then soared by 51.95% to $671.6 million in 2024, then gained by 7.52% to $722.2 million in 2025, then dropped by 11.93% to $636.0 million in 2026.
- Business Quant data shows VRDN's Common Equity at $636.0 million in Q1 2026, $722.2 million in Q4 2025, and $503.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 662.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 662.10 Mn |
| Mar 31, 2026 | 636.01 Mn |
| Dec 31, 2025 | 722.17 Mn |
| Sep 30, 2025 | 502.97 Mn |
| Jun 30, 2025 | 515.17 Mn |
| Mar 31, 2025 | 604.47 Mn |
| Dec 31, 2024 | 671.64 Mn |
| Sep 30, 2024 | 707.50 Mn |
| Jun 30, 2024 | 529.34 Mn |
| Mar 31, 2024 | 582.53 Mn |
| Dec 31, 2023 | 442.02 Mn |
| Sep 30, 2023 | 283.58 Mn |
| Jun 30, 2023 | 315.86 Mn |
| Mar 31, 2023 | 350.55 Mn |
| Dec 31, 2022 | 395.06 Mn |
| Sep 30, 2022 | 409.01 Mn |
| Jun 30, 2022 | 141.90 Mn |
| Mar 31, 2022 | 166.64 Mn |
| Dec 31, 2021 | 187.72 Mn |
| Sep 30, 2021 | 204.59 Mn |